Leptospirosis is a common zoonotic disease worldwide, especially in tropical areas, which is associated with human exposure to pathogenic *Leptospira*. Here we describe an ongoing outbreak investigation and the public health response to human leptospirosis cases linked to exposure to contaminated recreational water bodies in Northern Israel.

Outbreak detection
==================

In 9 August 2018, 15 cases, including a group of soldiers travelling together, with an acute febrile syndrome consistent with acute leptospirosis were notified from various hospitals across Israel, instigating an outbreak investigation. A potential common exposure was quickly recognised as being linked to recreational activities (including water rafting or kayaking) in several popular water bodies in Northern Israel, during the 3 weeks before onset of illness. Of note is that the implicated water bodies are heavily attended each year by the public in July and August. During recent years and especially in 2018, multi-year drought conditions resulted in seasonally low water levels in the region. Public water bodies in Israel are routinely monitored and inspected for faecal contamination according to national regulations for recreational water quality and in the past have been required to close to the public due to abnormal faecal contamination levels during the summertime.

Immediate public health response
================================

The public health response, led by the Public Health Services of the Israeli Ministry of Health (MOH), included the formation of a multi-disciplinary outbreak control team. This team included a range of experts and stakeholders such as infectious disease specialists, epidemiologists, microbiologists, the Veterinary Services at the Ministry of Agriculture, the Nature and Parks Authority and the National Water Authority and Water company (Mekorot) and communication specialists. An outbreak case definition formulated collaboratively by the outbreak control team can be seen in the [Box](#b1){ref-type="boxed-text"}.

###### Case definition for leptospirosis outbreak, formulated by the outbreak control team, Israel, 14 August, 2018

**Suspected cases^a^**: individuals with any acute febrile illness accompanied by relevant symptoms or signs (modified from United States Centers for Disease Control and Prevention \[[@r1]\]), occurring within 2 days to 3 weeks of recent exposure to the relevant water bodies^b^.

**Probable cases**: suspected cases with a borderline-positive serology to leptospirosis (1:50 to 1:150).

**Confirmed cases**: suspected cases with laboratory confirmation of leptospirosis using molecular techniques (positive real-time polymerase chain reaction (PCR) for pathogenic leptospires applied on blood or urine samples) and/or serology (positive microagglutination test (MAT), using a panel of 24 antigens, defined as a single titre of 1:200 or more or a fourfold rise of titre over 10 or more days).

^a^At the time of writing, convalescent-phase sera have not yet been received and tested for the vast majority of cases and since initial negative PCR and/or MAT cannot rule out leptospirosis, patients meeting the case definition but with negative serology were classified as 'suspected' and not excluded.

^b^The case definition initially included four body sites (Zavitan, Yehudiya, Meshushim and Zaki). Three additional sites were added a few days later following the recognition of additional exposure sites.

Active retrospective and prospective surveillance of leptospirosis cases was initiated. The MOH notified the public through various media channels about the outbreak and recommended that individuals meeting the case definition seek medical advice in community clinics or hospitals. The MOH issued detailed guidance for healthcare professionals concerning the diagnosis, treatment alternatives and reporting of suspected leptospirosis in the community and hospital settings. Empiric age-based antimicrobial therapy was recommended for suspected cases at the discretion of attending physicians. Antimicrobial prophylaxis and personal protective equipment were recommended for potential occupational exposures (e.g. water inspectors in the region). The seven water bodies linked to suspected leptospirosis cases were closed to the public until further notice and the closure was publicised through a variety of media channels.

Public health microbiology response
===================================

Based on continuous risk assessment, the MOH increased the frequency of recreational water quality sampling to two to three times per week at the implicated sites (Public Health Laboratory, Haifa), as well as in a range of other water bodies in Northern Israel where human illness had not been reported. Under the assumption (and in line with the epidemiological hypothesis) that faecal coliforms could serve as a surrogate marker for animal-derived contamination of water, the microbial thresholds for site closure were lowered from 1,000 to 400 colony-forming units (cfu)/100mL of faecal coliforms. The National Reference Laboratory for Leptospirosis (Israel Institute for Biological Research (IIBR), Ness Ziona), mounted a surge response in order to process a large number of clinical samples by means of a duplex real-time polymerase chain reaction (PCR) for pathogenic leptospires (targeting the 16S rRNA and the *LipL32* genes) and microagglutination test (MAT). A real-time PCR testing of water for the implicated water bodies has also been performed on a 'research use only' basis. In addition, a series of quantitative molecular tests using the microbial source tracking (MST) strategy for detection of faecal contamination source was deployed (Mekorot Central Laboratory) \[[@r2]\].

Outbreak description
====================

As of 31 August 2018, 619 suspected cases of leptospirosis had been notified to the MOH, of which 33 were laboratory-confirmed and three were probable. The remaining cases had initial negative MAT and/or PCR (leptospirosis not ruled out). The epidemic curve of the outbreak is shown in [Figure 1](#f1){ref-type="fig"}.

![Epidemic curve for human leptospirosis in Northern Israel, June--August 2018 (n = 619)](1800486-f1){#f1}

Retrospective case finding identified a confirmed case of infection afflicting a water inspector dating back to June 2018. The characteristics of laboratory-confirmed cases are summarised in Table 1. Of the 33 laboratory-confirmed and three probable cases, 31 were male and the median age was 20 years (mean 25, range 7-64). The incubation period ranged from 2--21 days (mean 9.9 days, median 10 days). Influenza-like symptoms were common while rash and conjunctivitis were rare. The majority (n = 31) of confirmed cases were hospitalised, 12 had hepatic or renal involvement and one patient developed pneumonia. Three were reported to have been admitted to an intensive-care unit; no deaths were reported. There was one travel-associated case reported in a German tourist who developed severe leptospirosis \[[@r3]\], it is thought that this case was exposed in early June.

###### Characteristics of laboratory-confirmed and probable cases of leptospirosis, Israel, June--August 2018 (n = 36)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Date of onset of illness in 2018   Incubation period (days)   Relevant exposure           Clinical symptoms                                                                        Illness severity                                         Laboratory results             Case-classification
  ---------------------------------- -------------------------- --------------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------ ---------------------
  28 June                            13                         Meshushim pool              Fever, chills, weakness, myalgia                                                         Hospitalised                                             MAT ≥ 1:200                    Confirmed

  1 July                             9                          Jordan Park / Arik Bridge   Fever, weakness, headache, myalgia, vomiting                                             Hospitalised, renal failure                              MAT ≥ 1:200                    Confirmed

  26 July                            2                          Meshushim pool              Fever, chills, weakness, headache, myalgia                                               Hospitalised, renal failure, elevated liver enzymes      MAT = 1:100                    Probable

  29 July                            2                          Zavitan stream              Fever, weakness, headache, myalgia, vomiting                                             Hospitalised, elevated creatinine and liver enzymes      MAT ≥ 1:200                    Confirmed

  31 July                            2                          Jordan Park / Arik Bridge   Fever, weakness, headache, myalgia                                                       Hospitalised                                             Positive PCR                   Confirmed

  1 August                           7                          Zavitan stream              Fever, chills, weakness, headache, myalgia                                               Hospitalised, renal failure, elevated liver enzymes      MAT ≥ 1:200                    Confirmed

  3 August                           10                         Yehudiya forest reserve     Fever, chills, weakness, headache                                                        Hospitalised                                             MAT ≥ 1:200                    Confirmed

  4 August                           12                         Yehudiya forest reserve     Fever, weakness, headache, vomiting                                                      Hospitalised                                             MAT ≥ 1:200                    Confirmed

  4 August                           8                          Meshushim pool              Fever, chills, weakness, headache, conjunctivitis, myalgia, cough, vomiting, diarrhoea   Hospitalised, renal failure, elevated liver enzymes      MAT ≥ 1:200                    Confirmed

  4 August                           7                          Yehudiya forest reserve     Fever, headache, myalgia, nausea,                                                        Hospitalised, pneumonia                                  MAT ≥ 1:200                    Confirmed

  4 August                           6                          Meshushim pool              Fever, chills, weakness, headache, myalgia                                               Hospitalised                                             MAT ≥ 1:200                    Confirmed

  4 August                           11                         Meshushim Pool              Fever, headache                                                                          Emergency department, immunocompromised at baseline      MAT [\> ]{.ul}1:200            Confirmed

  4 August                           10                         Meshushim Pool              Fever, chills, weakness, headache, myalgia,                                              Ambulatory                                               MAT [\> ]{.ul}1:200            Confirmed

  5 August                           12                         Yehudiya forest reserve     Fever, chills, weakness, headache, myalgia                                               Hospitalised, renal failure and elevated liver enzymes   Positive PCR,\                 Confirmed
                                                                                                                                                                                                                                              MAT ≥ 1:200                    

  5 August                           9                          Meshushim pool              Fever, headache, myalgia vomiting, rash                                                  Hospitalised                                             MAT 1:100                      Probable

  5 August                           9                          Zaki stream                 Fever, weakness, myalgia, vomiting                                                       Hospitalised                                             Positive PCR,\                 Confirmed
                                                                                                                                                                                                                                              MAT ≥ 1:200                    

  5 August                           5                          Meshushim pool              Pending investigation                                                                    Pending investigation                                    MAT ≥ 1:200 (seroconversion)   Confirmed

  6 August                           19                         Zaki stream                 Fever, chills, weakness, headache, myalgia                                               Hospitalised                                             MAT ≥ 1:200                    Confirmed

  6 August                           14                         Yehudiya forest reserve     Fever, chills, weakness, headache, myalgia                                               Hospitalised                                             MAT ≥ 1:200                    Confirmed

  6 August                           2                          Yehudiya forest reserve     Fever, weakness, myalgia, headache, vomiting, diarrhoea, leukopenia, thrombocytopenia    Hospitalised, intensive care                             Positive PCR                   Confirmed

  7 August                           10                         Meshushim pool              Fever, headache, myalgia, jaundice                                                       Hospitalised                                             MAT ≥ 1:200 (seroconversion)   Confirmed

  8 August                           4                          The Majrasa                 Fever, chills, weakness, headache, myalgia                                               Hospitalised, intensive care                             Positive PCR                   Confirmed

  8 August                           15                         Zaki stream                 Fever, weakness, headache, myalgia                                                       Hospitalised, renal failure, elevated liver enzymes      MAT ≥ 1:200                    Confirmed

  9 August                           9                          Meshushim pool              Fever, weakness, headache, myalgia, arthralgia                                           Emergency department                                     Positive PCR                   Confirmed

  10 August                          12                         Meshushim pool              Fever, weakness, headache, myalgia, vomiting, diarrhoea                                  Hospitalised                                             Positive PCR                   Confirmed

  11 August                          12                         The Majrasa                 Fever, chills, weakness, headache, myalgia, vomiting                                     Hospitalised, intensive care                             MAT = 1:50                     Probable

  14 August                          19                         Yehudiya forest reserve     Pending investigation                                                                    Pending investigation                                    MAT [\> ]{.ul}1:200            Confirmed

  14 August                          11                         Jordan Park / Arik Bridge   Fever, chills, weakness, headache, myalgia                                               Hospitalised                                             Positive PCR                   Confirmed

  15 August                          21                         Yehudiya forest reserve     Fever, chills, weakness, myalgia, conjunctivitis                                         Hospitalised, elevated liver enzymes                     Positive PCR                   Confirmed

  15 August                          10                         Jordan Park / Arik Bridge   Fever, chills, weakness, headache, jaundice                                              Hospitalised, elevated liver enzymes                     Positive PCR                   Confirmed

  15 August                          13                         Zavitan Stream              Fever, chills, weakness, headache, myalgia, vomiting                                     Hospitalised                                             Positive PCR                   Confirmed

  16 August                          10                         Gilabon Stream              Fever, weakness, headache, myalgia, vomiting                                             Hospitalised                                             Positive PCR                   Confirmed

  16 August                          6                          Meshushim Pool              Fever, chills, myalgia, vomiting, conjunctivitis                                         Hospitalised                                             Positive PCR                   Confirmed

  17 August                          8                          Gilabon Stream              Fever, weakness, headache, vomiting                                                      Hospitalised                                             Positive PCR                   Confirmed

  19 August                          9                          Jordan Park / Arik Bridge   Fever, chills, weakness, headache, myalgia, diarrhoea, conjunctivitis                    Hospitalised, renal failure                              Positive PCR                   Confirmed

  19 August                          17                         Gilabon Stream              Fever, chills, weakness, myalgia                                                         Hospitalised, renal failure                              Positive PCR                   Confirmed
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MAT: microagglutination test; PCR: Polymerase chain reaction.

The geographic distribution of cases is shown in [Figure 2](#f2){ref-type="fig"}. Exposure data were available for 540 cases (87.2%); all 36 confirmed and probable cases had exposures to one or more of seven recreational water bodies in the weeks before onset of illness; for the remaining 504 suspected cases, 645 potential exposures were noted, of which 423 (65.5%) involved the implicated water bodies.

![Spatial distribution of leptospirosis cases in Northern Israel, June--August 2018 (n = 540)](1800486-f2){#f2}

Environmental investigation
===========================

Laboratory surveillance for faecal contamination ([Figure 3](#f3){ref-type="fig"}) revealed abnormal faecal coliform counts on repeated measurements from all water bodies, supporting the decision for site closure to the public. Subsequent MST of the initial four water sources identified heavy faecal contamination attributed to wild boar and cattle, with only a trace of human faeces. Positive serological tests by MAT were reactive against a range of serovars as commonly seen in early leptospirosis. The Pomona and Burgas antigens (Serovars Pomona and Balcanica, respectively) were particularly reactive (seven and ten cases, respectively) with titres ranging from 1:200 to 1:1,600. The Pomona serovar, in particular, is naturally adapted to wild boar and there have been recent reports from the Israeli veterinary authorities on the emergence of *L*. Pomona infection in wild boar and cattle in Northern Israel \[[@r4]\]. Faecal contamination of water bodies from wild boar and cattle origin, in combination with clinical infection with the Pomona serovar, support human infection acquired through exposure to animal excretions during recreational activity under favourable conditions for transmission, i.e. drought and relative water stagnation.

![Faecal contamination of water bodies in Northern Israel, June--August 2018](1800486-f3){#f3}

Discussion
==========

The severity of leptospirosis varies greatly, ranging from asymptomatic infection to mild influenza-like illness to a severe life-threatening infection (Weil's disease) \[[@r5]\]. The severity of infection depends on the type of exposure, the human host and the infecting serovar. Human infection commonly involves direct or indirect exposure to infected urine originating from animal reservoirs, this can occur both recreationally or occupationally \[[@r6]\]. While many cases are sporadic, outbreaks of human leptospirosis have been occasionally reported.

Human leptospirosis is uncommon in Israel; data from the MOH surveillance of notifiable diseases suggest less than 10 confirmed cases have occurred per annum over the last decades \[[@r7]\]. An outbreak of seven cases of leptospirosis acquired during combat training of soldiers was reported in 2002 and was caused by a low pathogenicity serovar (*L*. Hardjo) commonly found in cattle in Israel \[[@r8]\]. The current outbreak is much larger and subject to ongoing investigation and case surveillance. To date it has involved considerable communication challenges, with respect to the risk of contracting leptospirosis in certain locations, while providing assurance for the safety of continued recreational activities in the region as a whole. Difficulty in obtaining accurate travel history for cases in the weeks following possible exposure was particularly challenging. To overcome challenges during this outbreak, communication strategies involved not only national web-based, electronic and printed media, but also externalisation of visual aids based on geographic information systems (GIS). Since the North of Israel is a popular site for domestic and international tourism, especially during the summer, cases may show up elsewhere in returning travellers. Individuals meeting the case definition may therefore be considered as suspected cases.

In addition, the relevant government agencies have used water originating from other regional water sources to help increase the water flow to the implicated water bodies; thus, reducing stagnation and helping to dilute and wash away faecal contamination. To date, four sites have been targeted for increased water flow, while monitoring of effectiveness continues using serial faecal coliform as well as MST testing. In the absence of validated regulatory tests for environmental contamination with pathogenic *Leptospira*, the criteria for re-opening of water bodies for the public visit are complex. Currently, they rely on a combination of epidemiological data and direct and indirect microbiological tests as part of an ongoing risk assessment.

Long-term solutions are currently being considered to prevent further water contamination. These include improved control of animal leptospirosis in ruminants, through employing repeated testing, antimicrobial treatment and vaccination with polyvalent vaccines containing the implicated serovar. In addition, solutions for prevention of further contamination by providing designated water sources (basins) and limiting natural water access of free-ranging animals are currently being considered and involve a cross-sectoral effort of multiple government offices.
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